Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine

The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (MDK-Nitisinone) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met: for use in p...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, April 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Tyrosinemias / Diet Therapy
Canada
Nitrobenzoates / Economics
Tyrosinemias / Drug Therapy
Cost-benefit Analysis
Insurance, Health, Reimbursement / Economics
Drug Costs
Nitrobenzoates / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (MDK-Nitisinone) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met: for use in patients with an established diagnosis of HT-1. The drug is prescribed by a physician with experience in the diagnosis and management of HT-1. The total cost of treatment with nitisinone (MDK-Nitisinone) should not exceed the drug plan cost of other nitisinone products
Item Description:"Final."
Physical Description:1 PDF file (8 pages)

Similar Items